Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal Assessment as MASH Therapies Expand SAN DIEGO, CA / ACCESS Newswire / ...

As the prevalence of liver disease continues to climb alongside diabetes and obesity, the role of the primary care physician is evolving from referral maker to frontline manager.

Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

Metabolic dysfunction-associated steatohepatitis, or MASH, is a disease at the intersection of metabolic and hepatic dysfunction — creating a complex clinical picture for people living with this ...

Longer treatment with an Akero Therapeutics drug in development for the liver disease MASH led to better results, including improvement in fibrosis, the liver scarring that is a hallmark of the ...

Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention. Panelists discuss how obesity and insulin ...